Title: Efficacy and Safety of Mirikizumab for Ulcerative Colitis: A Systematic Review and
Meta-analysis of Randomized Controlled
Version: 2 Date: 06 Dec 2024
Reviewer:  Vito Annese
Reviewer's report:
Abu Elainein et al report in this meta-analysis the RTCs using Mirikizumab in UC.
The study is correctly  evaluated with standard methodology  and good quality figures.
Reasons of some herterogeneity among studies is well explained and data analyzed after
exclusion.
The major limitation is that already other 4 network meta-analyses have included  these studies
and already published in 2024, thus reducing the interest; however, this indeed at the moment
is the only meta-analsysis specifically on mirikizumab.
The paper would also benefit of a revision of the english language to improve clarity.
Minor
In the abstract and introduction ustekinumab is not mentioned as standadd of care and approved
therapy for ulcerative colitis. Please correct
Title: Efficacy and Safety of Mirikizumab for Ulcerative Colitis: A Systematic Review and
Meta-analysis of Randomized Controlled
Version: 2 Date: 06 Dec 2024
Reviewer:  Vito Annese
Reviewer's report:
Abu Elainein et al report in this meta-analysis the RTCs using Mirikizumab in UC.
The study is correctly  evaluated with standard methodology  and good quality figures.
Reasons of some herterogeneity among studies is well explained and data analyzed after
exclusion.
The major limitation is that already other 4 network meta-analyses have included  these studies
and already published in 2024, thus reducing the interest; however, this indeed at the moment
is the only meta-analsysis specifically on mirikizumab.
The paper would also benefit of a revision of the english language to improve clarity.
Minor
In the abstract and introduction ustekinumab is not mentioned as standadd of care and approved
therapy for ulcerative colitis. Please correct
Please review this paper.
user
Title: Efficacy and Safety of Mirikizumab for Ulcerative Colitis: A Systematic Review and
Meta-analysis of Randomized Controlled
Version: 2 Date: 06 Dec 2024
Reviewer:  Vito Annese
Reviewer's report:
Abu Elainein et al report in this meta-analysis the RTCs using Mirikizumab in UC.
The study is correctly  evaluated with standard methodology  and good quality figures.
Reasons of some herterogeneity among studies is well explained and data analyzed after
exclusion.
The major limitation is that already other 4 network meta-analyses have included  these studies
and already published in 2024, thus reducing the interest; however, this indeed at the moment
is the only meta-analsysis specifically on mirikizumab.
The paper would also benefit of a revision of the english language to improve clarity.
Minor
In the abstract and introduction ustekinumab is not mentioned as standadd of care and approved
therapy for ulcerative colitis. Please correct
assistant